Compare TRDA & CDZI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRDA | CDZI |
|---|---|---|
| Founded | 2016 | 1983 |
| Country | United States | United States |
| Employees | 183 | 25 |
| Industry | Biotechnology: Pharmaceutical Preparations | Water Supply |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.6M | 443.8M |
| IPO Year | 2021 | N/A |
| Metric | TRDA | CDZI |
|---|---|---|
| Price | $12.67 | $5.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 191.6K | ★ 619.1K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,421,000.00 | N/A |
| Revenue This Year | $51.37 | $64.02 |
| Revenue Next Year | $46.98 | $28.16 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $2.13 |
| 52 Week High | $12.93 | $6.96 |
| Indicator | TRDA | CDZI |
|---|---|---|
| Relative Strength Index (RSI) | 59.95 | 46.48 |
| Support Level | $9.59 | $5.21 |
| Resistance Level | N/A | $5.99 |
| Average True Range (ATR) | 0.86 | 0.26 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 84.15 | 19.23 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, which derives key revenue, and comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, which provides water filtration solutions for impaired or contaminated groundwater sources.